Loretta P. Ngu
Exeter, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.
Journal: Blood advances
Published: June 30, 2023
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.
Journal: Leukemia
Published: May 30, 2023
Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma: a rare cause of ileal intussusception.
Journal: BMJ case reports
Published: December 30, 2022
Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients.
Journal: British journal of haematology
Published: December 11, 2022
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study.
Journal: Hematology (Amsterdam, Netherlands)
Published: June 06, 2022
Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
Journal: British journal of haematology
Published: January 06, 2020
Autoimmune haemolytic anaemia associated with Epstein Barr virus infection as a severe late complication after kidney transplantation and successful treatment with rituximab: case report.
Journal: BMC nephrology
Published: February 17, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026